Helixmith Co., Ltd.   Report issue

For profit Phase 3
Founded: Seoul Korea, Republic of (1996)

Organization Overview

First Clinical Trial
2020
NCT05361031
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Helixmith Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

vm202 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Diabetic Neuropathies (Phase 3)

Motor Neuron Disease (Phase 2)

Pain (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1